Ono Pharmaceutical (OTCMKTS:OPHLY) Shares Down 1.8% – Time to Sell?

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLYGet Free Report)’s share price was down 1.8% during mid-day trading on Monday . The company traded as low as $4.89 and last traded at $4.89. Approximately 73,909 shares were traded during mid-day trading, an increase of 132% from the average session volume of 31,898 shares. The stock had previously closed at $4.98.

Ono Pharmaceutical Trading Down 1.8%

The business’s 50-day simple moving average is $4.89 and its two-hundred day simple moving average is $4.99.

Ono Pharmaceutical Company Profile

(Get Free Report)

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.

Read More

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.